BIOGEN: JP Morgan Increases Price Target to $185, Up from $175
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 14 hours ago
0mins
Should l Buy BIIB?
Source: moomoo
- Price Increase Announcement: J.P. Morgan has raised its price target for BioGen from $175 to $185.
- Market Implications: This adjustment reflects J.P. Morgan's updated outlook on BioGen's performance and potential growth in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 190.070
Low
143.00
Averages
204.45
High
246.00
Current: 190.070
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BIOGEN: JP Morgan Increases Price Target to $185, Up from $175
- Price Increase Announcement: J.P. Morgan has raised its price target for BioGen from $175 to $185.
- Market Implications: This adjustment reflects J.P. Morgan's updated outlook on BioGen's performance and potential growth in the market.
See More
Biogen (BIIB) Q3 2024 Earnings Transcript
See More
UBS Upgrades Biogen, Sees 21% Upside Potential
- Rating Upgrade: UBS has upgraded Biogen's rating from neutral to buy and raised its price target from $185 to $225, indicating a potential 21% upside, reflecting optimism about the company's future performance.
- Market Outperformance: Biogen has gained nearly 6% year-to-date in 2026, outperforming the broader market, although its stock still trades at a discount compared to the S&P 500 healthcare sector, highlighting its undervalued potential.
- Pipeline Catalysts: The investigational Alzheimer's treatment BIIB080 is set for clinical studies this summer, with analysts predicting positive results could boost the stock by 10-25%, enhancing market confidence.
- Upcoming Data Releases: The company will release phase-three trial data for its lupus drug litifilimab in Q4, and positive results could lead to a stock increase of over 20%, supporting its commercial growth trajectory.
See More
Latest Rating Changes on Wall Street
- Airbnb Upgrade: Wells Fargo upgraded Airbnb from equal weight to overweight, projecting revenue growth of 6% to 11% and EPS growth of 7% to 12% by 2027, indicating strong innovation and market potential.
- Positive Outlook for SharonAI: Compass Point initiated coverage on SharonAI with a buy rating, highlighting that its first major contract will drive scale and that its Australian capacity build provides a credible market base for deployment.
- Biogen's Multiple Catalysts: UBS upgraded Biogen to buy with a price target of $225, citing increasing confidence in several pipeline catalysts expected to drive stock price higher over the next 12-15 months.
- Twilio's Strategic Improvement: Bank of America upgraded Twilio from underperform to buy with a price target of $190, believing its strategic positioning in AI will lead to positive growth inflections for the company.
See More
Stock Performance Analysis of Multiple Companies
- AES Corporation Stock Rating: Analysts describe AES Corporation's stock as incredibly attractive, stating it is 'ridiculously cheap' and recommending investors consider buying, which could lead to significant returns in the future.
- InterDigital Market Outlook: While InterDigital is viewed primarily as a telecom stock rather than an AI play, analysts express optimism about its performance, suggesting that the recent price drop presents a good opportunity for investors, potentially drawing renewed interest.
- Infleqtion Investment Strategy: Infleqtion's stock has experienced a parabolic rise, with analysts advising investors to take profits at high levels and buy back at lower prices to achieve better investment returns.
- Biogen Upgrade Analysis: Biogen recently received an upgrade from Wells Fargo, with analysts highlighting its potential across multiple revenue streams, including Alzheimer's, suggesting that its future performance merits reevaluation and indicating strong growth prospects.
See More
Midday Market Moves: Notable Stock Fluctuations
- Stanley Black & Decker Surge: Stanley Black & Decker's stock rose over 4% after the company stated that recent changes to Section 232 tariffs would not materially impact its full-year forecast, indicating strong confidence in its financial outlook.
- Fermi Stock Plunge: Shares of energy infrastructure developer Fermi fell more than 22% following the resignation of CFO Miles Everson and the recent departure of CEO Toby Neugebauer, raising concerns about the company's leadership stability and future direction.
- Biogen's Strategic Move: Biogen's stock increased nearly 3% after agreeing to pay $850 million for exclusive rights to sell felzartamab in China, which underscores its strategic expansion in the immune-related disease treatment market.
- Fertilizer Stocks Fluctuate: Fertilizer stocks experienced volatility as CF Industries rose nearly 2% due to ongoing shipping disruptions in the Strait of Hormuz, while Dow and LyondellBasell Industries also saw gains of about 4% and 2%, respectively, reflecting market reactions to supply chain challenges.
See More
BIOGEN: JP Morgan Increases Price Target to $185, Up from $175
- Price Increase Announcement: J.P. Morgan has raised its price target for BioGen from $175 to $185.
- Market Implications: This adjustment reflects J.P. Morgan's updated outlook on BioGen's performance and potential growth in the market.
See More
Biogen (BIIB) Q3 2024 Earnings Transcript
See More
UBS Upgrades Biogen, Sees 21% Upside Potential
- Rating Upgrade: UBS has upgraded Biogen's rating from neutral to buy and raised its price target from $185 to $225, indicating a potential 21% upside, reflecting optimism about the company's future performance.
- Market Outperformance: Biogen has gained nearly 6% year-to-date in 2026, outperforming the broader market, although its stock still trades at a discount compared to the S&P 500 healthcare sector, highlighting its undervalued potential.
- Pipeline Catalysts: The investigational Alzheimer's treatment BIIB080 is set for clinical studies this summer, with analysts predicting positive results could boost the stock by 10-25%, enhancing market confidence.
- Upcoming Data Releases: The company will release phase-three trial data for its lupus drug litifilimab in Q4, and positive results could lead to a stock increase of over 20%, supporting its commercial growth trajectory.
See More
Latest Rating Changes on Wall Street
- Airbnb Upgrade: Wells Fargo upgraded Airbnb from equal weight to overweight, projecting revenue growth of 6% to 11% and EPS growth of 7% to 12% by 2027, indicating strong innovation and market potential.
- Positive Outlook for SharonAI: Compass Point initiated coverage on SharonAI with a buy rating, highlighting that its first major contract will drive scale and that its Australian capacity build provides a credible market base for deployment.
- Biogen's Multiple Catalysts: UBS upgraded Biogen to buy with a price target of $225, citing increasing confidence in several pipeline catalysts expected to drive stock price higher over the next 12-15 months.
- Twilio's Strategic Improvement: Bank of America upgraded Twilio from underperform to buy with a price target of $190, believing its strategic positioning in AI will lead to positive growth inflections for the company.
See More
Stock Performance Analysis of Multiple Companies
- AES Corporation Stock Rating: Analysts describe AES Corporation's stock as incredibly attractive, stating it is 'ridiculously cheap' and recommending investors consider buying, which could lead to significant returns in the future.
- InterDigital Market Outlook: While InterDigital is viewed primarily as a telecom stock rather than an AI play, analysts express optimism about its performance, suggesting that the recent price drop presents a good opportunity for investors, potentially drawing renewed interest.
- Infleqtion Investment Strategy: Infleqtion's stock has experienced a parabolic rise, with analysts advising investors to take profits at high levels and buy back at lower prices to achieve better investment returns.
- Biogen Upgrade Analysis: Biogen recently received an upgrade from Wells Fargo, with analysts highlighting its potential across multiple revenue streams, including Alzheimer's, suggesting that its future performance merits reevaluation and indicating strong growth prospects.
See More
Midday Market Moves: Notable Stock Fluctuations
- Stanley Black & Decker Surge: Stanley Black & Decker's stock rose over 4% after the company stated that recent changes to Section 232 tariffs would not materially impact its full-year forecast, indicating strong confidence in its financial outlook.
- Fermi Stock Plunge: Shares of energy infrastructure developer Fermi fell more than 22% following the resignation of CFO Miles Everson and the recent departure of CEO Toby Neugebauer, raising concerns about the company's leadership stability and future direction.
- Biogen's Strategic Move: Biogen's stock increased nearly 3% after agreeing to pay $850 million for exclusive rights to sell felzartamab in China, which underscores its strategic expansion in the immune-related disease treatment market.
- Fertilizer Stocks Fluctuate: Fertilizer stocks experienced volatility as CF Industries rose nearly 2% due to ongoing shipping disruptions in the Strait of Hormuz, while Dow and LyondellBasell Industries also saw gains of about 4% and 2%, respectively, reflecting market reactions to supply chain challenges.
See More
